Trial · NCT04626791
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
NCT04626791, Phase 2, Active not recruiting, Academic and Community Cancer Research United
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma. Trials, record NCT04626791. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04626791
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
- NCT number
- NCT04626791
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 41 participants, actual
- Lead sponsor
- Academic and Community Cancer Research United
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Acalabrutinib, Bortezomib, Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Prednisone, Rituximab, Rituximab and Hyaluronidase Human
- First posted
- 2020-11-13
- Last updated
- 2026-08-25
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Complete Responses to Therapy (Complete Metabolic Response [CMR]) | 29 months | Measured according to Lugano criteria. A success is defined as a CMR as the objective status at the end of treatment. The percentage of successes will be estimated by the number of successes divided by the total number of evaluable patients. 95% confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner. |
| Secondary | Number of Patients Experiencing at Least One Grade 3 or Greater Adverse Event | 29 months | The number of patients experiencing at least one grade 3 or greater adverse event will be reported. |
| Secondary | Progression-free Survival | 15 months | The proportion of patients alive and progression free with 95% CI will be estimated using the method of Kaplan-Meier. |
| Secondary | Overall Survival | 18 months | The proportion of participants alive and 95% CI will be estimated using the method of Kaplan-Meier. |
| Secondary | Feasibility of Stem Cell Collection | 29 months | The percentage of patients successfully collecting at least 2 x 10\^6 CD34 cells/kg pt body weight will be calculated and reported. |
| Secondary | Successful Proceeding to Autologous Stem Cell Transplant (ASCT) | 29 months | The feasibility of stem cell collection will be determined by the proportion of patients successfully collecting at least 2 x 10\^6 CD34 cells/kg pt body weight divided by the total number of evaluable patients proceeding to ASCT. |
| Other | MRD Rate | Up to completion of study treatment | Measured by sequencing. MRD results will be reported descriptively, and explored for correlation with clinical factors and patient outcomes. |
| Other | Minimal Residual Disease (MRD) Rate | Up to completion of study treatment | Measured by flow. MRD results will be reported descriptively, and explored for correlation with clinical factors and patient outcomes. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42305039 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | WILLMAN, CHERYL LYNN | MAYO CLINIC ROCHESTER | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04626791
GET https://conductscience.org/api/trials/v1/NCT04626791/registered